论文部分内容阅读
目的观察罗格列酮对代谢综合征患者冠状动脉介入治疗(PCI)术后再狭窄率及代谢指标的影响。方法随机分成对照组(按常规治疗)和罗格列酮组(常规治疗+罗格列酮治疗),在行PCI术前1d,罗格列酮组患者在原来用药的基础上予罗格列酮8mg,poqd,以后以4mgd治疗;对照组采用原来药物治疗,不加用罗格列酮。两组患者术后常规随访6个月。结果罗格列酮组升高了HDL-C,降低了TG、CRP,有统计学意义(P<0.05);有降低PCI术后支架内再狭窄率趋势;未增加不良心血管事件发生率。结论罗格列酮能改善代谢综合征患者的血糖、血脂代谢指标,并可减轻炎症反应,有益于减少PCI术后支架内再狭窄。
Objective To observe the effect of rosiglitazone on the rate of restenosis and the metabolic parameters after coronary intervention (PCI) in patients with metabolic syndrome. Methods Randomly divided into control group (conventional treatment) and rosiglitazone group (conventional treatment + rosiglitazone treatment), 1d before PCI, patients in rosiglitazone group were treated with rosiglitazone Ketone 8mg, poqd, after 4mgd treatment; control group using the original drug treatment, without the use of rosiglitazone. Two groups of patients were followed up routinely for 6 months. Results Rosiglitazone increased HDL-C, decreased TG, CRP, with statistical significance (P <0.05); reduced the rate of in-stent restenosis after PCI; did not increase the incidence of adverse cardiovascular events. Conclusion Rosiglitazone can improve blood glucose and lipid metabolism in patients with metabolic syndrome and reduce the inflammatory reaction, which is beneficial to reduce in-stent restenosis after PCI.